BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35045365)

  • 1. Cost-Effectiveness of Treatment Strategies for Spinal Metastases.
    Kowalchuk RO; Mullikin TC; Kim DK; Morris JM; Ebner DK; Harmsen WS; Merrell KW; Beriwal S; Waddle MR; Kim H
    Pract Radiat Oncol; 2022; 12(3):236-244. PubMed ID: 35045365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases.
    Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):556-63. PubMed ID: 25680599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Compared With Radiofrequency Ablation for Inoperable Colorectal Liver Metastases.
    Kim H; Gill B; Beriwal S; Huq MS; Roberts MS; Smith KJ
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1175-83. PubMed ID: 27130789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study.
    Pollom EL; Lee K; Durkee BY; Grade M; Mokhtari DA; Wahl DR; Feng M; Kothary N; Koong AC; Owens DK; Goldhaber-Fiebert J; Chang DT
    Radiology; 2017 May; 283(2):460-468. PubMed ID: 28045603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for up to 10 brain metastases.
    Lester-Coll NH; Dosoretz AP; Magnuson WJ; Laurans MS; Chiang VL; Yu JB
    J Neurosurg; 2016 Dec; 125(Suppl 1):18-25. PubMed ID: 27903191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) for Early Stage Renal Cell Carcinoma (RCC).
    Donovan EK; Xie F; Louie AV; Chu W; Siva S; Kapoor A; Swaminath A
    Clin Genitourin Cancer; 2022 Oct; 20(5):e353-e361. PubMed ID: 35490099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Economic Analysis of SC24 in Canada: A Randomized Study of SBRT Compared With Conventional Palliative RT for Spinal Metastases.
    Kerba M; Lourenco RA; Sahgal A; Cardet RF; Siva S; Ding K; Myrehaug SD; Masucci GL; Brundage M; Parulekar WR
    Int J Radiat Oncol Biol Phys; 2024 Jan; ():. PubMed ID: 38218455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of External Beam Radiation Therapy versus Percutaneous Image-Guided Cryoablation for Palliation of Uncomplicated Bone Metastases.
    Chang EM; Shaverdian N; Capiro N; Steinberg ML; Raldow AC
    J Vasc Interv Radiol; 2020 Aug; 31(8):1221-1232. PubMed ID: 32674872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non-Small Cell Lung Cancer Based on Mutational Status.
    Kim H; Vargo JA; Ling DC; Beriwal S; Smith KJ
    Am J Clin Oncol; 2019 Nov; 42(11):837-844. PubMed ID: 31644441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re-irradiation stereotactic body radiotherapy for spinal metastases: a multi-institutional outcome analysis.
    Hashmi A; Guckenberger M; Kersh R; Gerszten PC; Mantel F; Grills IS; Flickinger JC; Shin JH; Fahim DK; Winey B; Oh K; John Cho BC; Létourneau D; Sheehan J; Sahgal A
    J Neurosurg Spine; 2016 Nov; 25(5):646-653. PubMed ID: 27341054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer.
    Sher DJ; Parikh RB; Mays-Jackson S; Punglia RS
    Am J Clin Oncol; 2014 Jun; 37(3):215-21. PubMed ID: 23275277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer.
    Lanni TB; Grills IS; Kestin LL; Robertson JM
    Am J Clin Oncol; 2011 Oct; 34(5):494-8. PubMed ID: 20805737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and cost-effectiveness analysis of external beam and stereotactic body radiation therapy in the treatment of spine metastases: a matched-pair analysis.
    Haley ML; Gerszten PC; Heron DE; Chang YF; Atteberry DS; Burton SA
    J Neurosurg Spine; 2011 Apr; 14(4):537-42. PubMed ID: 21314284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer.
    Kim H; Vargo JA; Beriwal S; Clump DA; Ohr JP; Ferris RL; Heron DE; Huq MS; Smith KJ
    Head Neck; 2018 Aug; 40(8):1743-1751. PubMed ID: 29537684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer.
    Murphy JD; Chang DT; Abelson J; Daly ME; Yeung HN; Nelson LM; Koong AC
    Cancer; 2012 Feb; 118(4):1119-29. PubMed ID: 21773972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck.
    Leung HW; Lang HC; Wang SY; Leung JH; Chan AL
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):489-495. PubMed ID: 33729079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spine Patient Optimal Radiosurgery Treatment for Symptomatic Metastatic Neoplasms (SPORTSMEN): a randomized phase II study protocol.
    McClelland S; Sun Y; Spratt DE
    Rep Pract Oncol Radiother; 2023; 28(3):379-388. PubMed ID: 37795393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness Analysis of Stereotactic Radiosurgery Alone Versus Stereotactic Radiosurgery with Upfront Whole Brain Radiation Therapy for Brain Metastases.
    Kim H; Rajagopalan MS; Beriwal S; Smith KJ
    Clin Oncol (R Coll Radiol); 2017 Oct; 29(10):e157-e164. PubMed ID: 28552517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
    Leung HW; Liu CF; Chan AL
    Radiat Oncol; 2016 May; 11():69. PubMed ID: 27193904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.